SENS
What one share of Senseonics Holdings holds
Industrial Instruments For Measurement, Display, and Control
We are a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (“CGM”) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy.
Senseonics Holdings’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.00 |
|---|---|
| Profit | −$2.25 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$2.00 |
| Cash and investments | $0.85 |
| Debt | $1.06 |
| Book value | $1.71 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $0.07 | −$9.84 | $0.11 | −$8.63 | — | −$1.04 |
| 2017 | $1.10 | −$10.19 | $0.06 | −$9.67 | — | $1.06 |
| 2018 | $2.40 | −$11.94 | $0.13 | −$11.66 | — | $8.06 |
| 2019 | $2.26 | −$12.24 | $0.11 | −$14.53 | — | −$0.85 |
| 2020 | $0.43 | −$15.37 | $0.02 | −$5.93 | — | −$10.85 |
| 2021 | $0.65 | −$14.32 | $0.01 | −$2.67 | — | −$8.30 |
| 2023 | $0.79 | −$2.20 | $0.01 | −$2.48 | — | $1.35 |
| 2024 | $0.71 | −$2.50 | $0.07 | −$1.99 | — | −$0.56 |
| 2025 | $0.84 | −$1.66 | $0.03 | −$1.44 | — | $1.48 |